ABOUT US

Our focus on the GSK-, glycogen synthase kinase- enzyme has led to the therapeutic candidate elraglusib, formerly known as 9-ING-41. Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such as checkpoint inhibitors. It is our belief that this versatile agent will improve clinical outcomes for patients suffering from advanced, hard-to-treat cancers.

LEADERSHIP

Daniel M. Schmitt
President & Chief Executive Officer
Andrew P. Mazar, Ph.D.
Chief Operating Officer
Paul Lytle
Chief Financial Officer
Stevens Reich
Vice President, Clinical Development
Richard Kenley
Vice President, Chemistry, Manufacturing, & Controls
Chris Seifarth
Vice President, Operations and Quality Assurance
Laura Kelly
Director of Clinical Operations
Austin Koukol
Project Manager for Operations and Translational Science

BOARD OF DIRECTORS

Director
Director
President & Chief Executive Officer

Scientific Advisory Board

TIMELINE

Take a look at the Actuate journey; where we’ve been, where we are, and where we are going. Click the button below to see our company’s history.